High Rates of Primary Mycobacterium avium Complex and Pneumocystis jiroveci Prophylaxis in the United States
- 1 September 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 43 (9) , III23-23
- https://doi.org/10.1097/01.mlr.0000175631.34438.1e
Abstract
National data from the mid-1990s demonstrated that many eligible patients with HIV infection do not receive prophylaxis for opportunistic infections (OIs) and that racial and gender disparities existed in OI prophylaxis receipt. We examined whether demographic disparities in use of OI prophylaxis persist in 2001 and if outpatient care is associated with OI prophylaxis utilization. Demographic, clinical, and pharmacy utilization data were collected from 10 U.S. HIV primary care sites in the HIV Research Network. This study consisted of adult patients (≥18 years old) in longitudinal HIV primary care. Indications for Pneumocystis jiroveci pneumonia (PCP) or Mycobacterium avium complex (MAC) prophylaxis were 2 or more CD4 counts less than 200 or 50 cells/mm3 during calendar year (CY) 2001, respectively. Using multivariate logistic regression, we examined demographic and clinical characteristics associated with receipt of PCP or MAC prophylaxis and the association of outpatient utilization with appropriate OI prophylaxis. Among eligible patients, 88.1% received PCP prophylaxis and 87.6% received MAC prophylaxis. Approximately 80% had 4 or more outpatient visits during CY 2001. Adjusting for care site, male gender (odds ratio [OR], 1.47), Medicare coverage (OR, 1.60), and having 4 or more outpatient visits in a year (OR, 2.34) were significantly associated with increased likelihood of PCP prophylaxis. Adjusting for care site, having 4 or more outpatient visits in a year (OR, 1.85) was associated with increased likelihood of receipt of MAC prophylaxis. There were no demographic or insurance characteristics associated with receipt of MAC prophylaxis. The overall prevalence of OI prophylaxis has increased since the mid-1990s, and previous racial and HIV risk factor disparities in receipt of OI prophylaxis have waned. Integration into the healthcare system is an important correlate of receiving OI prophylaxis.Keywords
This publication has 25 references indexed in Scilit:
- The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and SpendingNew England Journal of Medicine, 2003
- Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literaturePublic Health Reports®, 2002
- 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus July 2001: DRAFTHIV Research & Clinical Practice, 2001
- Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Reducing racial disparities in transplant activation:Whom should we target?American Journal of Kidney Diseases, 2001
- Prevalence and Predictors of Highly Active Antiretroviral Therapy Use in Patients With HIV Infection in the United StatesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- The association between primary source of ambulatory care and access to a outcomes of treatment among AIDS patientsInternational Journal for Quality in Health Care, 1999
- Changes in insurance status and access to care for persons with AIDS in the Boston Health Study.American Journal of Public Health, 1994
- Access to therapy in the multicenter AIDS Cohort Study, 1989–1992Journal of Clinical Epidemiology, 1994
- Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban CommunityNew England Journal of Medicine, 1994